Officials in the Trump administration are pushing to make testosterone prescriptions easier for men to obtain, according to Fortune. The move adds momentum to a long-running debate over testosterone replacement therapy, its medical value, and how tightly access should be controlled.

The report says only 12% of testosterone prescriptions are considered medically necessary, a figure that suggests much of the market may already extend beyond clear clinical need. If access is loosened further, critics argue the balance could shift even more from treatment of diagnosed hormone problems toward broader lifestyle use.

Supporters of wider availability often point to growing demand and the appeal of treatments aimed at symptoms linked to low testosterone. But opponents warn that expanding prescribing standards could blur the line between legitimate care and elective enhancement, especially as questions about benefits and risks remain part of the discussion.

The policy shift highlights a broader change in Washington's approach to men's health and prescription oversight. As testosterone use continues to rise, the argument over who should get the hormone — and for what reason — is likely to stay at the center of the health policy conversation.